ABSTRACT
Colorectal cancer is the second leading cause of cancer-related death worldwide. For metastatic colorectal cancer (mCRC) patients, it is recommended, as first-line treatment, chemotherapy (CT) based on doublet cytotoxic combinations of fluorouracil, leucovorin, and irinotecan (FOLFIRI) and fluorouracil, leucovorin, and oxaliplatin (FOLFOX). In addition to CT, biological (targeted agents) are indicated in the first-line treatment, unless contraindicated. In this context, most of mCRC patients are likely to progress and to change from first line to second line treatment when they develop resistance to first-line treatment options. It is in this second line setting where Aflibercept offers an alternative and effective therapeutic option, thought its specific mechanism of action for different patients profile: RAS mutant, RAS wild-type (wt), BRAF mutant, potentially resectable and elderly patients. In this paper, a panel of experienced oncologists specialized in the management of mCRC experts have reviewed and selected scientific evidence focused on Aflibercept as an alternative treatment (AU)
Subject(s)
Humans , Angiogenesis Inhibitors/therapeutic use , Antineoplastic Agents, Immunological/therapeutic use , Colorectal Neoplasms/drug therapy , Antineoplastic Combined Chemotherapy Protocols , Bevacizumab/therapeutic use , Clinical Trials, Phase III as Topic , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , Fluorouracil/therapeutic use , Leucovorin/therapeutic use , Age FactorsABSTRACT
Colorectal cancer is the second leading cause of cancer-related death worldwide. For metastatic colorectal cancer (mCRC) patients, it is recommended, as first-line treatment, chemotherapy (CT) based on doublet cytotoxic combinations of fluorouracil, leucovorin, and irinotecan (FOLFIRI) and fluorouracil, leucovorin, and oxaliplatin (FOLFOX). In addition to CT, biological (targeted agents) are indicated in the first-line treatment, unless contraindicated. In this context, most of mCRC patients are likely to progress and to change from first line to second line treatment when they develop resistance to first-line treatment options. It is in this second line setting where Aflibercept offers an alternative and effective therapeutic option, thought its specific mechanism of action for different patient's profile: RAS mutant, RAS wild-type (wt), BRAF mutant, potentially resectable and elderly patients. In this paper, a panel of experienced oncologists specialized in the management of mCRC experts have reviewed and selected scientific evidence focused on Aflibercept as an alternative treatment.
Subject(s)
Angiogenesis Inhibitors/therapeutic use , Colorectal Neoplasms/drug therapy , Drug Substitution , Receptors, Vascular Endothelial Growth Factor/therapeutic use , Recombinant Fusion Proteins/therapeutic use , Age Factors , Antineoplastic Agents, Immunological/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bevacizumab/therapeutic use , Camptothecin/analogs & derivatives , Camptothecin/therapeutic use , Clinical Trials, Phase III as Topic , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , Fluorouracil/therapeutic use , Genes, ras , Humans , Leucovorin/therapeutic use , Liver Neoplasms/secondary , Liver Neoplasms/surgery , Lung Neoplasms/secondary , Lung Neoplasms/surgery , Mutation , Neovascularization, Pathologic/drug therapy , Organoplatinum Compounds/therapeutic use , Proto-Oncogene Proteins B-raf/genetics , Vascular Endothelial Growth Factor A/antagonists & inhibitorsABSTRACT
El carcinoma ovárico de célula pequeña hipercalcémicoes un tumor raro y agresivo con mayor incidenciaen mujeres jóvenes.La hipercalcemia es una de sus características clínicas.El tratamiento multidisciplinar parece incrementarla supervivencia en un número pequeño de casos.Presentamos el caso de una mujer diagnosticadade este tipo de tumor, su evolución clínica y el tratamientoque recibió
The hypercalcemic ovarian small cell carcinomais a very rare aggressive tumor affecting young women.Hypercalcemia is among its clinical features.Prognosis is poor despite aggressive treatment,but combined treatment seems to increase survivalin a small subset of patients.We report a case of a woman diagnosed of hypercalcemicovary small cell cancer, her clinical evolution and the treatment she received (AU)
